Literature DB >> 582025

Thyroid binding antibodies and other immunological abnormalities in patients with Graves' ophthalmopathy: effect of treatment with cyclophosphamide.

J R Wall, C R Strakosch, S L Fang, S H Ingbar, L E Braverman.   

Abstract

Patients with Graves' ophthalmopathy were studied for a possible role of thyroid binding antibodies (TBAb) as measured by a radioreceptor assay, and for in vitro evidence of immunoreactivity to orbital antigens. The effect of cyclophosphamide (CY) treatment on the immunological parameters and the clinical course of the eye disease was also studied. The mean TBAb index for all patients with eye disease was significantly less than that for the normal and for patients with Graves hyperthyroidism who lacked eye disease. The mean TBAb index for patients with ophthalmopathy and past or present hyperthyroidism was significantly less than for those patients with eye disease but no associated hyperthyroidism ('euthyroid Graves' disease'). TBAb levels did not correlate with the severity of duration of the eye disease and did not change during treatment with CY. Significant titres of serum antibodies against human eye muscle extract or subcellular fractions, or macrophage inhibitory factor (MIF) production in response to human orbital tissue extract were not detected in patients with eye disease. The congestive changes improved in all patients treated with CY, although the degree of proptosis and eye muscle involvement improved in only 3 of 24 and 11 of 20 patients respectively with these abnormalities. TBAb are unlikely to play a role in the pathogenesis of Graves' ophthalmopathy and the hyperthyroidism and eye disease should be considered separate autoimmune disorders. The apparently anomalous finding of a higher mean TBAb index in patients with eye disease and hyperthyroidism than in those with hyperthyroidiam alone may reflect a more severe defect of suppressor T cell function in the former group. Because evidence for specific immunoreactivity against orbital antigens was not found in this study other approaches to defining the underlying immunological mechanisms will have to be sought.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582025     DOI: 10.1111/j.1365-2265.1979.tb03036.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

Review 1.  Autoimmunity in Graves' ophthalmopathy: a review.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

Review 2.  Immunosuppressant therapy of thyroid eye disease.

Authors:  G Kahaly; J Beyer
Journal:  Klin Wochenschr       Date:  1988-11-01

3.  In vitro production of thyroid-binding antibodies by peripheral blood lymphocytes from patients with Graves' disease: nonspecific responses associated with culture supernatant proteins.

Authors:  J R Wall; C R Strakosch; A Trewin; D M Joyner
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

Review 4.  Risk factors for development or deterioration of Graves' ophthalmopathy.

Authors:  Marius N Stan; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

Review 5.  Ocular manifestations of Graves' disease: a review.

Authors:  A P Weetman; A M McGregor; R Hall
Journal:  J R Soc Med       Date:  1984-11       Impact factor: 5.344

6.  Graves' hyperthyroidism and ophthalmopathy following treatment of spontaneous hypothyroidism with levothyroxine.

Authors:  P A Easton; J R Wall
Journal:  Can Med Assoc J       Date:  1981-07-01       Impact factor: 8.262

7.  Squamous cell carcinoma of the eyelid masquerading as 'malignant' ophthalmopathy of Graves's disease.

Authors:  H C Ford; J W Delahunt; C A Teague
Journal:  Br J Ophthalmol       Date:  1983-09       Impact factor: 4.638

8.  A specific IgG in Graves' ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity.

Authors:  P Kendall-Taylor; S Atkinson; M Holcombe
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-21

9.  Luekocyte adherence inhibition in response to human orbital and lacrimal extracts in patients with Graves' ophthalmopathy.

Authors:  J R Wall; B A Walters; C Grant
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

10.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.